Publications

Latest publication 06/11/2014

Activation of neurotensin receptor type 1 attenuates locomotor activity

Intracerebroventricular administration of neurotensin (NT) suppresses locomotor activity. However, the brain regions that mediate the locomotor...

Array
(
    [id_prestablog_news] => 570
    [id_shop] => 1
    [date] => 2014-06-11 00:00:00
    [date_modification] => 2024-02-09 14:15:11
    [langues] => ["1","2"]
    [actif] => 1
    [slide] => 0
    [url_redirect] => 
    [average_rating] => 
    [number_rating] => 
    [author_id] => 1
    [featured] => 0
    [ishero] => 0
    [prim_key] => 1115
    [id_lang] => 1
    [title] => Activation of neurotensin receptor type 1 attenuates locomotor activity
    [paragraph] => Activation of neurotensin receptor type 1 attenuates locomotor activity
    [content] => 
Authors
C. A. Vadniea, D. J. Hintona, S. Choib, Y. Choib, C. L. Ruby

 Lab
Mayo Clinic College of Medicine, Rochester, USA
Journal
Neuropharmacology
Abstract
Intracerebroventricular administration of neurotensin (NT) suppresses locomotor activity. However, the brain regions that mediate the locomotor depressant effect of NT and receptor subtype-specific mechanisms involved are unclear. Using a brain-penetrating, selective NT receptor type 1 (NTS1) agonist PD149163, we investigated the effect of systemic and brain region-specific NTS1 activation on locomotor activity. Systemic administration of PD149163 attenuated the locomotor activity of C57BL/6J mice both in a novel environment and in their homecage. However, mice developed tolerance to the hypolocomotor effect of PD149163 (0.1 mg/kg, i.p.). Since NTS1 is known to modulate dopaminergic signaling, we examined whether PD149163 blocks dopamine receptor-mediated hyperactivity. Pretreatment with PD149163 (0.1 or 0.05 mg/kg, i.p.) inhibited D2R agonist bromocriptine (8 mg/kg, i.p.)-mediated hyperactivity. D1R agonist SKF-81297 (8 mg/kg, i.p.)-induced hyperlocomotion was only inhibited by 0.1 mg/kg of PD149163. Since the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) have been implicated in the behavioral effects of NT, we examined whether microinjection of PD149163 into these regions reduces locomotion. Microinjection of PD149163 (2 pmol) into the NAc, but not the mPFC suppressed locomotor activity. In summary, our results indicate that systemic and intra-NAc activation of NTS1 is sufficient to reduce locomotion and NTS1 activation inhibits D2R-mediated hyperactivity. Our study will be helpful to identify pharmacological factors and a possible therapeutic window for NTS1-targeted therapies for movement disorders.
BIOSEB Instruments Used
Grip strength test (BIO-GS3)

Keywords/Topics
Locomotion; Motor control
    [meta_description] => 
    [meta_keywords] => http://www.sciencedirect.com/science/article/pii/S0028390814002226
    [meta_title] => 
    [link_rewrite] => activation-of-neurotensin-receptor-type-1-attenuates-locomotor-activity
    [actif_langue] => 1
    [read] => 1400
    [count_comments] => 0
    [id] => 570
    [categories] => Array
        (
            [55] => Array
                (
                    [id_prestablog_categorie] => 55
                    [title] => Locomotion
                    [link_rewrite] => Locomotion
                )

            [14] => Array
                (
                    [id_prestablog_categorie] => 14
                    [title] => Motor control
                    [link_rewrite] => Motor-control
                )

            [2] => Array
                (
                    [id_prestablog_categorie] => 2
                    [title] => Publications
                    [link_rewrite] => publications
                )

        )

    [authors] => 
    [paragraph_crop] => Activation of neurotensin receptor type 1 attenuates locomotor activity
    [link_for_unique] => 1
    [products_liaison] => Array
        (
            [48] => Array
                (
                    [name] => Grip strength test
                    [description_short] => 
An easy way to objectively quantify the muscular strength of mice and rats, and to assess the effect of drugs, toxins, muscular (i.e. myopathy) and neurodegenerative diseases on muscular degeneration. It is widely used in conjunction with the ROTAROD motor coordination test: a normally coordinated rodent will show a decreased latency to fall off the rotating rod if its muscular strength is low. The Grip Strength Test is a must for your research on activity, motor control & coordination, and is particularly well suited for studies on Parkinson's & Huntington's disease.
New features GS4 - 2023: Color display with permanent backlight screen for easier reading, reset by footswitch, Improved battery time, Larger data memory of 500 values, Animal counter, USB port (charging/data transfer)

                    [thumb] => 
                    [img_empty] => /var/www/vhosts/de3310.ispfr.net/bioseb2024/modules/prestablog/views/img/product_link_white.jpg
                    [image_presente] => 1
                    [link] => https://bioseb.com/en/activity-motor-control-coordination/48-grip-strength-test.html
                )

        )

)
1